According to Intra-Cellular Therapies's latest financial reports the company's total liabilities are $0.13 B. A companyโs total liabilities is the sum of all current and non-current debts and obligations.
Year | Total liabilities | Change |
---|---|---|
2023-12-31 | $0.13 B | 38.66% |
2022-12-31 | $98.71 M | 37.04% |
2021-12-31 | $72.03 M | 19.15% |
2020-12-31 | $60.45 M | 7.61% |
2019-12-31 | $56.17 M | 42.26% |
2018-12-31 | $39.49 M | 131.63% |
2017-12-31 | $17.04 M | 27.23% |
2016-12-31 | $13.4 M | 70.48% |
2015-12-31 | $7.86 M | -25.54% |
2014-12-31 | $10.55 M | 54.48% |
2013-12-31 | $6.83 M | 140.67% |
2013-03-31 | $0.02 M | |
2012-12-31 | $2.83 M |
Company | Total liabilities | differencediff. | Country |
---|---|---|---|
Xencor XNCR | $0.28 B | 107.17% | ๐บ๐ธ USA |
MediciNova MNOV | $3.89 M | -97.16% | ๐บ๐ธ USA |
Curis CRIS | $57.61 M | -57.91% | ๐บ๐ธ USA |